Clinical Trials Logo

TP53 wt Allele clinical trials

View clinical trials related to TP53 wt Allele.

Filter by:
  • None
  • Page 1

NCT ID: NCT03732352 Active, not recruiting - Glioblastoma Clinical Trials

18F-FDG PET and Osimertinib in Evaluating Glucose Utilization in Patients With EGFR Activated Recurrent Glioblastoma

Start date: November 28, 2018
Phase: Phase 2
Study type: Interventional

This phase II trial studies how well fludeoxyglucose F-18 (18F-FDG) positron emission tomography (PET) and osimertinib works in evaluating glucose utilization in patients with EGFR activated glioblastoma. Osimertinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. 18F-FDG PET imaging may help to detect changes in tumor glucose utilization, which may allow investigators to obtain an early read out on the impact of osimertinib on recurrent glioblastoma patients whose tumors have EGFR activation.

NCT ID: NCT03725436 Active, not recruiting - Clinical trials for Advanced Malignant Solid Neoplasm

ALRN-6924 and Paclitaxel in Treating Patients With Advanced, Metastatic, or Unresectable Solid Tumors

Start date: January 24, 2019
Phase: Phase 1
Study type: Interventional

This phase Ib trial studies the side effects and best dose of ALRN-6924 when given together with paclitaxel in treating patients with solid tumors that have spread to other places in the body or cannot be removed by surgery. Drugs used in chemotherapy, such as ALRN-6924 and paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading.